List of Excipients in Branded Drug CLONIDINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TruPharma LLC	CLONIDINE	clonidine	52817-375	CELLULOSE, MICROCRYSTALLINE
TruPharma LLC	CLONIDINE	clonidine	52817-375	CROSPOVIDONE
TruPharma LLC	CLONIDINE	clonidine	52817-375	HYPROMELLOSE

Generic Drugs Containing CLONIDINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	clonidine	0378-0871	MINERAL OIL
Mylan Pharmaceuticals Inc	clonidine	0378-0871	SILICON DIOXIDE
XGen Pharmaceuticals DJB Inc	clonidine	39822-2000	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in CLONIDINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE 2208
1	ISOPROPYL PALMITATE

Clonidine Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: September 24, 2026

Clonidine is a low-cost, mature antihypertensive and central alpha-2 adrenergic agonist with commercial opportunities concentrated in formulation differentiation rather than compound exclusivity. The strongest opportunities are extended-release oral products, pediatric-friendly dosage forms, transdermal delivery, abuse-resistant packaging, and lifecycle products that improve adherence or reduce withdrawal risk.

What pharmaceutical products contain clonidine?

Clonidine hydrochloride is marketed in several dosage forms and therapeutic settings.

Product or dosage form	Typical use	Formulation opportunity
Immediate-release tablets	Hypertension; off-label ADHD, withdrawal, migraine and vasomotor symptoms	Low-cost generic supply, orally disintegrating tablets, low-dose pediatric formats
Extended-release tablets	ADHD in children and adolescents	Release-control polymers, dose flexibility, pediatric swallowability
Transdermal patches	Hypertension	Adhesive performance, skin tolerability, smaller patch size, improved residual drug control
Injection or epidural solution	Severe pain or anesthesia-related use in selected settings	Preservative strategy, low-extractables packaging, hospital supply
Compounded oral liquids	Pediatric and geriatric use	Taste masking, chemical stability, unit-dose packaging
Combination products	Potential hypertension or symptom-management combinations	Fixed-dose combinations and differentiated adherence profiles

Catapres tablets and Catapres-TTS patches established the original commercial platforms for clonidine hydrochloride. Kapvay extended-release tablets expanded the product into attention-deficit/hyperactivity disorder treatment. FDA-approved clonidine products have been supplemented by generic tablets and extended-release products distributed by multiple manufacturers (FDA, 2024a; DailyMed, 2024a).

Clonidine is pharmacologically potent at low doses. That creates a technical need for content uniformity, low-dose blending control, dose flexibility and packaging that limits medication errors.

What excipients are used in clonidine tablets?

Clonidine excipients vary by manufacturer, strength and release profile. Common functional categories include:

Excipient category	Examples	Function
Fillers	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Tablet mass and compressibility
Binders	Povidone, pregelatinized starch, hydroxypropyl cellulose	Granule and tablet strength
Disintegrants	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Lubricants	Magnesium stearate, stearic acid, sodium stearyl fumarate	Ejection and manufacturing control
Glidants	Colloidal silicon dioxide, talc	Powder flow
Film coatings	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protection, identification and swallowability
Release-control polymers	Hypromellose, ethylcellulose, methacrylate copolymers	Extended drug release
Sweeteners and flavors	Sucralose, aspartame, mannitol, fruit flavors	Taste masking in pediatric products
Suspending agents	Xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose blends	Oral liquid physical stability
Adhesive components	Polyisobutylene, silicone adhesives, acrylic polymers	Transdermal attachment and drug delivery

The selected excipient system must be evaluated against clonidine’s low dose, high potency and pharmacokinetic sensitivity. A formulation can be technically acceptable while still creating clinically relevant differences in early exposure, sedation, hypotension or rebound hypertension.

FDA-approved labeling is the primary source for the exact inactive-ingredient composition of a marketed product. The formulation of one generic manufacturer should not be assumed to represent the composition of another (DailyMed, 2024a; FDA, 2024b).

How should an immediate-release clonidine tablet be formulated?

Immediate-release clonidine tablets should prioritize dose uniformity, rapid disintegration and mechanical robustness.

A practical development platform is a direct-compression or dry-granulation system using microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide and a low-level lubricant. Lactose or mannitol can be added when a higher tablet weight or improved mouthfeel is required.

The main development risks are:

1. Low-dose content uniformity.
2. Segregation of clonidine during blending or transfer.
3. Excessive lubricant exposure, which can slow dissolution.
4. Tablet weight variation at very low strengths.
5. Inconsistent splitting of scored tablets.

For low-strength tablets, geometric dilution, controlled particle-size distribution and validated blend sampling are important. A higher tablet weight may improve manufacturing control, but it can reduce swallowability and increase pediatric administration difficulty.

A differentiated generic could use:

• A smaller tablet with improved dose uniformity.
• A scored tablet supporting dose titration.
• An orally disintegrating tablet for patients unable to swallow.
• A mini-tablet platform for pediatric use.
• Unit-dose packaging with strength-specific color coding.

An orally disintegrating dosage form must control moisture sensitivity, friability and in-mouth disintegration time. Mannitol, crospovidone and taste-masking polymers are common starting points, but the formulation must avoid rapid drug release that increases peak exposure.

What excipients are appropriate for extended-release clonidine?

Extended-release clonidine requires a controlled-release matrix or coated multiparticulate system that limits dose dumping and maintains a predictable exposure profile.

Hypromellose matrix tablets are a practical platform. Polymer viscosity, loading level, tablet porosity and compression force determine the release curve. Ethylcellulose or methacrylate-based coatings can provide additional control but increase manufacturing complexity.

A development program should evaluate:

Parameter	Commercial relevance
Polymer concentration	Controls release duration and robustness
Polymer viscosity	Affects gel strength and dissolution
Tablet hardness	Changes liquid ingress and release rate
Food effect	Can alter exposure and patient instructions
Alcohol sensitivity	Screens for dose dumping
Tablet splitting or crushing	Determines labeling restrictions
pH-dependent release	Determines gastrointestinal robustness
In vitro-in vivo relationship	Supports formulation changes and scale-up

A matrix tablet can be lower cost than a multiparticulate capsule, but multiparticulates may offer better dose flexibility and reduced sensitivity to local gastrointestinal conditions. They also permit sprinkle administration if the particles maintain release characteristics after mixing with soft food.

The commercial value of an extended-release product is strongest when it provides a clear administration advantage over immediate-release clonidine. Potential claims include once-daily dosing, improved adherence, smoother symptom control or reduced daytime sedation. These claims require clinical and pharmacokinetic support and may not be available through a simple abbreviated generic pathway.

What excipients improve pediatric clonidine products?

Pediatric formulation is the clearest excipient-driven opportunity for clonidine.

Clonidine has a bitter or unpleasant taste profile, and pediatric doses may require liquid administration or tablet manipulation. A pediatric liquid should address taste, sedimentation, dose measurement and chemical stability.

Useful formulation approaches include:

• Flavored aqueous suspension.
• Clear or near-clear oral solution where stability permits.
• Powder for reconstitution.
• Unit-dose oral syringes.
• Low-volume, high-concentration liquid.
• Mini-tablets or orally disintegrating tablets.
• Sprinkle capsules containing controlled-release particles.

Potential excipient systems include a suspending vehicle based on xanthan gum or microcrystalline cellulose and carboxymethylcellulose, combined with a compatible sweetener and flavor. Preservatives may be needed for multidose aqueous products, but preservative selection must account for pH, container compatibility and pediatric exposure.

A unit-dose liquid can command a premium over a multidose bottle by reducing dosing errors and improving pharmacy workflow. The strongest value proposition is a stable product with a calibrated oral syringe and a formulation that avoids refrigeration.

The product must also account for accidental ingestion risk. Child-resistant packaging, small fill volumes and clear strength labeling are important risk-control features.

What excipients and materials are used in clonidine transdermal patches?

Transdermal clonidine is a delivery-system product rather than a conventional tablet. Its commercial performance depends on the drug-in-adhesive system, backing layer, release liner, permeation behavior and adhesion profile.

Key materials include:

• Polyisobutylene or silicone adhesive.
• Acrylic adhesive systems.
• Polyethylene or polyester backing films.
• Release liners with controlled peel force.
• Permeation-modifying excipients, where justified.
• Antioxidants or stabilizers where required.
• Skin-contact layers designed to limit irritation.

The main technical risks are adhesion loss, edge lift, crystallization, residual drug after wear, skin irritation and variability across patients with different skin characteristics.

Commercial improvements could include:

1. Smaller patch dimensions.
2. Better adherence during bathing and exercise.
3. Reduced skin irritation.
4. Lower residual drug content after use.
5. Easier removal without tearing.
6. Clearer dose and replacement-day markings.
7. Tamper-evident packaging.
8. A design that reduces accidental transfer to children or caregivers.

A transdermal reformulation may require more than an ANDA if the delivery system, pharmacokinetics or labeling differs materially from the reference product. The regulatory pathway depends on the proposed product’s relationship to the listed drug and the extent of formulation and device changes (FDA, 1999; FDA, 2024c).

What is the FDA regulatory status of clonidine products?

Clonidine hydrochloride is an approved active pharmaceutical ingredient with multiple FDA-approved dosage forms. Immediate-release tablets and transdermal systems are long-established products. Extended-release clonidine tablets were approved for ADHD under the Kapvay brand.

The relevant regulatory pathways include:

Product type	Likely pathway
Conventional generic tablet	ANDA under section 505(j)
Generic extended-release tablet	ANDA with comparative release and bioequivalence requirements
Generic transdermal system	ANDA or other pathway determined by FDA product-specific requirements
New oral liquid	505(b)(2) or ANDA, depending on reference-product relationship
New pediatric formulation	505(b)(2), ANDA or supplemental application
New combination product	NDA or 505(b)(2)
Hospital injection product	ANDA, 505(b)(2) or other applicable pathway

FDA approval does not establish that all clonidine products are interchangeable across dosage forms. Immediate-release tablets, extended-release tablets and transdermal systems have different exposure profiles and cannot be substituted solely because they contain the same active ingredient.

What patents protect clonidine products?

The original composition-of-matter protection for clonidine has expired. Current commercial barriers are primarily formulation, delivery-system, regulatory and manufacturing barriers.

Protection category	Current commercial relevance
Clonidine compound patent	Expired
Original immediate-release tablet patents	Expired or commercially ineffective
Original transdermal platform patents	Expired or substantially weakened by age
Extended-release formulation patents	Historical protection; expiration must be confirmed by patent family
Method-of-use patents	Potentially relevant only for narrow, enforceable claims
Pediatric formulation patents	Possible for specific dosage forms or administration methods
Manufacturing patents	Relevant if they cover a non-obvious process or impurity-control method
Trademark protection	May remain for brand names but does not block generic entry

The Orange Book status should be assessed by product and NDA, not by active ingredient alone. A patent listed against an extended-release product would not necessarily block an immediate-release tablet, and a method-of-use listing may not prevent approval for a non-infringing indication.

Paragraph IV risk is limited for old immediate-release clonidine products because the market has been generic for years. The greater patent-review issue is a new extended-release, transdermal or pediatric formulation that relies on a specific delivery technology. Any applicant pursuing an ANDA must review current Orange Book listings, FDA patent certifications and applicable litigation under the Hatch-Waxman framework (FDA, 2024b; USPTO, 2024).

When does clonidine lose exclusivity?

Clonidine’s basic active-ingredient exclusivity has already expired. The relevant commercial question is whether a specific dosage form retains enforceable formulation or use protection.

Exclusivity type	Status
Compound patent exclusivity	Expired
Original brand market exclusivity	Expired
Conventional tablet generic entry	Established
Transdermal generic entry	Established or commercially available in multiple markets
Extended-release product exclusivity	Historical and product-specific
Current pediatric exclusivity	No broad active-ingredient exclusivity expected
Regulatory exclusivity for a new reformulation	Possible only if a new NDA or 505(b)(2) qualifies

The absence of compound exclusivity does not eliminate litigation risk. A reformulated product may have patents covering dissolution profiles, polymer ratios, particle systems, patch architecture, dosing schedules or particular patient populations.

Which companies are challenging clonidine products?

Clonidine is supplied by a broad generic field rather than a single dominant challenger. Generic manufacturers and labelers have included major U.S. suppliers such as Teva, Mylan/Viatris, Actavis/Amneal, Sandoz, Par Pharmaceutical and various contract manufacturers, depending on dosage form and market period.

The competitive structure differs by product:

• Immediate-release tablets have intense price competition.
• Extended-release tablets have fewer technically capable suppliers.
• Transdermal patches have higher manufacturing and quality barriers.
• Oral liquids and pediatric dosage forms have fewer approved commercial options.
• Hospital products compete on supply reliability, packaging and contract pricing.

A new entrant is more likely to win through supply continuity, formulation convenience or customer-specific packaging than through active-ingredient differentiation.

How strong is the clonidine patent estate?

The clonidine patent estate is weak for the active ingredient and mature dosage forms but can be meaningful for a new delivery platform.

A practical strength assessment is:

Patent area	Strength
Active ingredient	Low
Immediate-release tablet	Low
Basic oral suspension	Low to moderate
Extended-release matrix	Moderate if claims are narrow and technically supported
Multiparticulate extended release	Moderate to high if claims cover distinctive architecture
Transdermal adhesive system	Moderate, dependent on claim scope and expiration
Pediatric taste-masked formulation	Low to moderate unless supported by unexpected performance
Manufacturing impurity control	Moderate if process-specific and difficult to design around
Combination product	Moderate, but dependent on clinical and method-of-use claims

Patent strength depends on claim breadth, prosecution history, written-description support, obviousness risk, remaining term and the availability of non-infringing alternatives. A formulation patent that claims a broad use of hypromellose or a conventional sweetener system is less defensible than one tied to a defined dissolution profile, stability result or delivery architecture.

What commercial opportunities exist for clonidine excipients?

The most attractive opportunities are differentiated products that solve administration or adherence problems.

Pediatric oral liquid

A ready-to-use, stable, palatable liquid with an oral syringe could address compounding variability and caregiver dosing errors. The product could target ADHD adjunctive treatment, withdrawal-related use and pediatric hypertension.

Orally disintegrating or mini-tablet product

This format could serve children, patients with dysphagia and adults who need low-dose titration. A premium is more defensible if the product maintains content uniformity and does not produce excessive early exposure.

Extended-release sprinkle formulation

Multiparticulates that can be administered with soft food would improve access for children who cannot swallow tablets. The formulation must preserve release performance after sprinkling and must not be crushed or chewed.

Improved transdermal patch

A smaller, skin-friendly patch with stronger adhesion and lower residual drug could compete in hypertension and adherence-sensitive populations. Device performance would be as important as excipient selection.

Hospital-ready packaging

Unit-dose syringes, ready-to-administer presentations and tamper-evident packaging can differentiate a mature injectable product. Hospitals may value reduced preparation time and fewer medication errors more than a lower unit price.

Contract formulation and excipient supply

Excipient suppliers can target:

• Low-dose direct-compression platforms.
• Taste-masking systems.
• Controlled-release polymer blends.
• Adhesive systems for transdermal delivery.
• Preserved and preservative-free liquid vehicles.
• Moisture-protective unit-dose packaging.
• Stability-indicating packaging for compounded or repackaged products.

What generic launch scenarios exist for clonidine?

The likely launch scenarios are segmented by dosage form.

Scenario	Entry risk	Commercial outlook
New immediate-release tablet	Low patent risk, high price pressure	Commodity supply
New extended-release tablet	Moderate technical and regulatory risk	Better margins if differentiated
New pediatric liquid	Moderate development risk	Attractive niche
New orally disintegrating tablet	Moderate formulation risk	Potential pharmacy and caregiver value
New transdermal patch	High development and manufacturing risk	Higher barrier and potentially better pricing
New combination product	High clinical and regulatory risk	Opportunity only with strong adherence or efficacy rationale

A generic applicant should expect limited pricing power for standard tablets. The return profile improves when the product reduces compounding, simplifies administration or solves a recognized supply problem.

What litigation and settlement issues affect clonidine?

Clonidine does not have the level of active patent litigation associated with newer branded therapies. Historical disputes have centered on generic entry, extended-release products, transdermal systems and the scope of formulation or use claims.

For a new applicant, the relevant legal checks are:

• Current Orange Book patent listings for the specific reference product.
• Paragraph IV certifications.
• ANDA litigation filed within the statutory window.
• Patent term adjustment and pediatric extensions.
• Continuation and divisional patent families.
• Settlement restrictions on launch timing.
• Product-specific labeling carve-outs.
• Inducement risk from ADHD, withdrawal or pain-related uses.

A patent clearance opinion should distinguish between the active ingredient, dosage form, release mechanism, indication and manufacturing process. A formulation may be commercially launchable for one indication while exposed to method-of-use claims for another.

Key Takeaways

• Clonidine compound exclusivity has expired, and conventional tablets are highly commoditized.
• Excipient-driven value is strongest in pediatric liquids, mini-tablets, orally disintegrating tablets, extended-release systems and transdermal patches.
• Low-dose content uniformity is a central manufacturing issue.
• Extended-release products require careful control of polymer level, viscosity, tablet hardness, food effect and dose dumping.
• Taste masking, calibrated dosing devices and child-resistant packaging can support pediatric differentiation.
• Transdermal opportunities depend on adhesive performance, skin tolerability and residual drug control.
• Patent risk is product-specific and concentrated in delivery systems, formulations, manufacturing processes and method-of-use claims.
• Standard immediate-release products offer low patent risk but weak pricing power.
• New dosage forms can support 505(b)(2), ANDA or NDA strategies depending on the relationship to the reference product.
• The most defensible commercial strategy combines formulation performance, regulatory convenience and reliable supply.

FAQs

Can clonidine be formulated as an oral solution?

Yes. Clonidine hydrochloride can be developed as a ready-to-use oral solution or suspension, but pH, chemical stability, preservative compatibility, taste and dose-measurement accuracy must be established.

Which excipient is best for extended-release clonidine?

No single excipient is universally best. Hypromellose is a common starting polymer for matrix tablets, while ethylcellulose and methacrylate polymers can support coated or multiparticulate systems. The choice depends on the target release profile and regulatory comparability strategy.

Is clonidine suitable for an orally disintegrating tablet?

Yes. An orally disintegrating tablet can address dysphagia and pediatric administration, but it must control taste, friability, moisture uptake and rapid drug release.

Does clonidine have biosimilar risk?

No. Clonidine is a small-molecule drug, not a biologic. Its competitive risk comes from generic and reformulated products, not biosimilars.

Can a new clonidine patch obtain meaningful patent protection?

Potentially. Protection is more plausible for a defined adhesive matrix, release architecture, residual-drug profile or manufacturing process than for the use of clonidine in a conventional patch.

References

1. DailyMed. (2024a). Clonidine hydrochloride tablet and extended-release tablet prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (1999). Guidance for industry: Transdermal and topical delivery systems: Product development and quality considerations. FDA.

3. U.S. Food and Drug Administration. (2024a). Drugs@FDA: FDA-approved drug products. FDA.

4. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Food and Drug Administration. (2024c). Product-specific guidances for generic drug development. FDA.

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: Clonidine hydrochloride. USP.

7. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System. USPTO.